What you need to know – and what you really should ask

Ever wondered whether enclomiphene is “legal” in the UK? The short answer: it’s highly restricted, and the landscape is complex. By the end of this article you’ll understand the legal status, risks, and what it means for you – especially if you run a business, import, or are involved in sport.

What is Enclomiphene?

Enclomiphene (sometimes called enclomifene or branded as Androxal® in earlier development) is one of the isomers of Clomiphene, developed for male hypogonadism and fertility applications.

However:

• It is not approved as a licensed medicine for general human use in the UK or EU.
• Its marketing authorisation was refused by the European Medicines Agency (EMA).
• Therefore its use falls into a grey area of “off‑label”, “research use only”, or unlicensed supply.

Core learning: What is Enclomiphene?

Legal Status in the UK (2026)

Enclomiphene is not approved for general human use in the UK, EU, or US.

Medicine or Supplement?

In the UK, the distinction is key. The Office for Product Safety & Standards (OPSS) has clarified that:

“It is illegal for either clomiphene or enclomiphene to be sold as a dietary supplement.” OPSS
This means any product marketed as a “supplement” but containing enclomiphene is unlawful under UK regulations.

Prescription Use

Because enclomiphene is not officially licensed for a standard indication in the UK, it cannot be legally prescribed under a standard licence for things like testosterone deficiency or general use. Many sources indicate there is no legitimate prescription route for enclomiphene in the UK. Therefore:

• Importation for personal use still carries legal risk.
• Sale or supply (especially commercially) is particularly risky.

Further reading: How researchers dose Enclomiphene

Laws & Regulations to Know

🇬🇧 United Kingdom

Relevant laws

• The principal UK law governing human medicines is the Human Medicines Regulations 2012 (HMRs). These regulations implement many of the EU directives and govern marketing authorisations, manufacturing, supply, etc of human medicinal products.
• For clinical trials of investigational medicinal products, the Medicines for Human Use (Clinical Trials) Regulations 2004 as amended (e.g., by the “Amendment (EU Exit) Regulations 2019”) apply. (See SI 2019/744) Legislation.gov.uk
• The Medicines and Healthcare products Regulatory Agency (MHRA) publishes guidance such as UK‑wide licensing for human medicines which references the HMRs. GOV.UK
• Also, the Office for Product Safety & Standards (OPSS) has issued guidance stating that “It is illegal for either clomiphene or enclomiphene to be sold as a dietary supplement” in the UK. OPSS

How that applies to Enclomiphene

• Because enclomiphene is not licensed (i.e., does not have a UK marketing authorisation under the HMRs) for general human use, it cannot legally be sold as a medicinal product for human use.
• Moreover, the OPSS guidance confirms that it cannot be sold as a “dietary supplement” (which is a separate regulatory route) because it is considered a drug. OPSS
• As a result, the only lawful way for enclomiphene to be used in the UK is likely under a clinical trial (investigational medicinal product) regime authorised by the MHRA under the clinical trials regulations, or via a “compounded medicine” route (which has its own restrictions), but not marketed freely.

In short: UK law says you must have a marketing authorisation (HMRs) to place a medicine on the market; for a drug without one, only investigational use permitted, or authorised import/special supply under strict conditions.

Further reading: Enclomiphene Mechanism of Action

🇪🇺 European Union

Relevant laws

• The key EU law is Directive 2001/83/EC “on the Community code relating to medicinal products for human use”. Art 6 states: “No medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities…” EUR-Lex
• Under this Directive, medicines require a full dossier (quality, safety, efficacy) to obtain a Marketing Authorisation (MA).
• A product without MA cannot legally be placed on the market for human use.

How that applies to Enclomiphene

• The EnCyzix product (containing enclomiphene) applied for marketing authorisation via the European Medicines Agency (EMA). On 25 Jan 2018 the EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion, recommending refusal of MA because benefits did not outweigh risks. European Medicines Agency (EMA)
• Since the MA was refused, the product cannot be legally marketed in the EU for that indication.
• Consequently, enclomiphene remains an unlicensed investigational substance in the EU: use outside of authorised clinical trials would be in breach of Directive 2001/83/EC (or national implementations thereof).

Thus, EU law effectively restricts enclomiphene’s use for human consumption unless a valid MA is granted – which has not been the case.

🇺🇸 United States

Relevant laws

• The primary statute is the Federal Food, Drug, and Cosmetic Act (FD&C Act). Section 505(a) (21 U.S.C. § 355(a)) states: “No person shall introduce or deliver for introduction into interstate commerce any new drug, unless an approval of an application filed pursuant to subsection (b) or (j) of this section is effective…” GovInfo
• The regulations for investigational new drugs are found in 21 CFR Part 312 (“Investigational New Drug Application”). Under § 312.2(a): the part “applies to all clinical investigations of products that are subject to section 505” and § 312.2(b)(1) says investigations of approved drugs may be exempt. eCFR
• Also, the FDA publishes information that “No FDA‑approved drugs contain enclomiphene as active ingredient”. U.S. Food and Drug Administration

How that applies to Enclomiphene

• Since enclomiphene has no approved New Drug Application (NDA) with the FDA (see press release that FDA issued a “Complete Response Letter” in 2015 rejecting the NDA). BioSpace
• Therefore it is a “new drug” under the FD&C Act, but not approved. Hence it cannot be marketed for human use. It can only be used under an IND (Investigational New Drug) status for clinical trials.
• The label for an investigational drug must carry: “Caution: New Drug – Limited by Federal (or United States) law to investigational use.” (§ 312.6) unr.edu

Thus, in the U.S., enclomiphene is restricted to investigational (clinical trial) use only unless and until an NDA is approved.

Summary Table

Jurisdiction	Key Legal Requirement	Status of Enclomiphene
UK	Marketing Authorisation required (HMRs) + cannot be sold as supplement (OPSS)	Not authorised → only investigational / special supply
EU	Marketing Authorisation required (Directive 2001/83/EC)	MA refused by EMA → only investigational
US	New Drug cannot be marketed without FDA approval (FD&C Act § 505)	No NDA approved → only investigational under an IND

• Medicines for human use in the UK must be author‑ised by the Medicines and Healthcare products Regulatory Agency (MHRA). If not authorised, supply may breach the Human Medicines Regulations.
• Products marketed as food supplements cannot contain unauthorized active substances. OPSS indicates enclomiphene cannot be sold as a supplement.
• For athletes: UK Anti‑Doping (UKAD) lists enclomiphene under prohibited substances (S4 category – hormone and metabolic modulators).

What This Means for Consumers & Businesses

For Consumers

• If used, you may be self‑experimenting with an unlicensed drug, with unknown safety/quality.
• As an athlete, use of enclomiphene may result in anti‑doping violations.
• Possession alone might not guarantee legality; importation and supply carry risk.

For Retailers or Suppliers

• Selling enclomiphene as a “supplement” is illegal under UK law per OPSS guidance.

Importation / Online Purchase

• Importing enclomiphene into the UK for personal use remains in a grey area. The consumer remains responsible for ensuring the product is lawful.
• Customs, MHRA, OPSS may seize unlicensed medicines or unauthorised imports.
• Legal status may change: always check latest guidance from MHRA and OPSS.

Quick Summary: “Legal” vs “Illegal”

Here’s a table to cut through the fog:

Scenario	Status in UK (2026)	Key note
Licensed prescribing of enclomiphene	❌ Not approved	No standard route
Sale of enclomiphene as a food/supplement	❌ Illegal	OPSS clearly states this OPSS
Use by athlete in sport	❌ Prohibited	UKAD lists it as banned
Importation for human use without licence	⚠️ High‑risk/grey	Subject to regulation, seizure risk
Research use with valid authorisation	✅ Possibly legal under strict conditions	Rare and controlled

Tips for Staying Compliant

• If you’re a business: treat enclomiphene as a prescription‑only medicine (POM) unless you have full authorisation.
• Always check MHRA and OPSS updates for any changes or enforcement actions.
• For athletes: avoid it entirely unless prescribed and compliant with anti‑doping rules.
• When hearing claims like “low dose enclomiphene supplement” – ask for evidence of authorisation, batch testing, regulatory compliance.

Looking Ahead: What to watch for

• Regulatory changes post‑Brexit could impact status of niche compounds like enclomiphene.
• MHRA may issue new guidelines or enforcement notices – stay updated.
• Anti‑doping agencies continue to monitor emerging substances.
• Market trends: unlicensed “research chemicals” may increase – volatility and risk rise accordingly.

Guidance for researchers: Enclomiphene side effects in studies

Final Word

In plain terms: no, enclomiphene is not legally available for general human use in the UK as a supplement or over‑the‑counter medicine. Its supply, sale or purchase outside proper prescription/authorisation is fraught with legal risk. If you’re an athlete, business owner or consumer, treat it as largely unapprovedand proceed only with full regulatory clarity and legal advice.